As Sequencing Moves Into Clinical Use, Insurers Balk

Julie Steenhuysen
(Reuters, June 19, 2014)
“Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests.As use of the new technology has grown, a number of insurers…have reacted by putting the brakes on reimbursement…Insurers are demanding proof that the results will lead to meaningful treatments among the estimated 2 million Americans with a serious, undiagnosed disease, still an unlikely prospect in the majority of cases.”
Full Article